VTechWorks staff will be away for the Thanksgiving holiday beginning at noon on Wednesday, November 27, through Friday, November 29. We will resume normal operations on Monday, December 2. Thank you for your patience.
 

Economic Feasibility of the Recovery of Therapeutic Proteins From the Milk of Transgenic Livestock

Simple item page
dc.contributor.authorElhadj, Selimen
dc.contributor.committeechairVelander, William H.en
dc.contributor.committeememberWilliams, Kimberly Forstenen
dc.contributor.committeememberDavis, Richey M.en
dc.contributor.departmentChemical Engineeringen
dc.date.accessioned2014-03-14T20:57:49Zen
dc.date.adate1998-05-12en
dc.date.available2014-03-14T20:57:49Zen
dc.date.issued1998-05-05en
dc.date.rdate1999-05-12en
dc.date.sdate1998-05-05en
dc.description.abstractThe recovery of pharmaceuticals from blood plasma is often expensive, limited, and is subject to contamination. The objective of this feasibility study is to present recovery designs and the most significant parameters affecting manufacturing costs of human Serum Albumin (hSA), human Protein C (hPC), and Factor VIII (FVIII) from the milk of transgenic livestock. All the processes presented are based on chromatography columns to achieve separation. The sensitivity of the manufacturing cost of the protein to various parameters are illustrated graphically and discussed, along with the cost distribution percentages for each type of process. It was found that manufacturing costs decrease with superficial velocity, expression levels, column yields, column capacities, and scale of production increases with all other parameters remaining constant. However the estimated cost decreases tend to level out at higher values of the parameters. Finally a judicious choice of separation scheme, such as Fall-Through (FT) versus Direct Adsorption (DA) for hSA production, can decrease the protein cost by as much as 38%, due to savings from wash and elution buffers. The costs associated with the production of hSA (DA process), hSA (FT process), hPC, and FVIII are 3.56, 2.20, 129, and 11,780 $/gr respectively. By means of the optimization of manufacturing parameters to reduce costs, key areas of emphasis for process development were identified.en
dc.description.degreeMaster of Engineeringen
dc.identifier.otheretd-41298-161018en
dc.identifier.sourceurlhttp://scholar.lib.vt.edu/theses/available/etd-41298-161018/en
dc.identifier.urihttp://hdl.handle.net/10919/37167en
dc.publisherVirginia Techen
dc.relation.haspartMajpaper.pdfen
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjecthuman serum albuminen
dc.subjecthuman protein Cen
dc.subjectfactor VIIIen
dc.subjecttherapeutic proteinen
dc.subjectmanufacturing costen
dc.subjectrecoveryen
dc.subjectmilken
dc.subjecttransgenicen
dc.titleEconomic Feasibility of the Recovery of Therapeutic Proteins From the Milk of Transgenic Livestocken
dc.typeMajor paperen
thesis.degree.disciplineChemical Engineeringen
thesis.degree.grantorVirginia Polytechnic Institute and State Universityen
thesis.degree.levelmastersen
thesis.degree.nameMaster of Engineeringen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Majpaper.pdf
Size:
61.47 KB
Format:
Adobe Portable Document Format
Download

Collections

Master's Papers and Projects